Ginkgo biloba extract EGb 761 (R) or pentoxifylline for the treatment of sudden deafness: A randomized, reference-controlled, double-blind study

Citation
C. Reisser et H. Weidauer, Ginkgo biloba extract EGb 761 (R) or pentoxifylline for the treatment of sudden deafness: A randomized, reference-controlled, double-blind study, ACT OTO-LAR, 121(5), 2001, pp. 579-584
Citations number
19
Categorie Soggetti
Otolaryngology,"da verificare
Journal title
ACTA OTO-LARYNGOLOGICA
ISSN journal
00016489 → ACNP
Volume
121
Issue
5
Year of publication
2001
Pages
579 - 584
Database
ISI
SICI code
0001-6489(200107)121:5<579:GBEE7(>2.0.ZU;2-R
Abstract
In a randomized, prospective, double-blind study involving 72 patients, the therapeutic efficacy of ginkgo extract EGb 761(R) (n = 37) was compared to that of pentoxifylline (n = 35) for the treatment of sudden deafness. The two therapeutic schedules were equally well tolerated and showed a statisti cally significant equivalence in improvement or in return to normal of the auditory thresholds in the two patient groups. Furthermore, no differences were found between the treatment groups with regard to the criteria for a r eturn to normal of speech discrimination and reduction of the tinnitus whic h arose at the same time as the sudden hearing loss. The patient's subjecti ve assessment of the treatment with regard to improvement in hearing and re duction in tinnitus suggested that Ginkgo biloba extract was more beneficia l than pentoxifylline. In summary, it was shown that treatment of sudden de afness with ginkgo special extract EGb 761 was as effective as treatment wi th pentoxifylline.